Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Bone Marrow Diseases

ClinicalTrials.gov lists 4,312 trials for Bone Marrow Diseases or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 184.

MeSH D001855 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 845 Phase 1/2 Phase 1/2 481 Phase 2 Phase 2 1,462 Phase 2/3 Phase 2/3 61 Phase 3 Phase 3 365 Phase 4 Phase 4 91 Not applicable Not applicable 297 Observational Observational 676 Phase 1 Phase 1 845 Phase 1/2 Phase 1/2 481 Phase 2 Phase 2 1,462 Phase 2/3 Phase 2/3 61 Phase 3 Phase 3 365 Phase 4 Phase 4 91 Not applicable Not applicable 297 Observational Observational 676

Trials per phase (log scale)

2 more sections with rows

65 of the 4,312 trials are tagged with Bone Marrow Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Bone Marrow Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Bone Marrow Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 199

1990: 1 trials (Phase 2 1) 1991: 2 trials (Observational 1, Phase 2 1) 1992: 3 trials (Not applicable 1, Phase 2 2) 1993: 9 trials (Phase 3 3, Phase 2 2, Phase 1/2 1, Phase 1 3) 1994: 10 trials (Phase 3 1, Phase 2 8, Phase 1 1) 1995: 18 trials (Observational 2, Not applicable 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 3, Phase 1 2) 1996: 23 trials (Observational 3, Not applicable 1, Phase 3 7, Phase 2 8, Phase 1/2 2, Phase 1 2) 1997: 29 trials (Observational 1, Not applicable 3, Phase 3 5, Phase 2 11, Phase 1/2 2, Phase 1 7) 1998: 60 trials (Observational 4, Not applicable 1, Phase 4 2, Phase 3 11, Phase 2/3 2, Phase 2 25, Phase 1/2 3, Phase 1 12) 1999: 67 trials (Observational 2, Not applicable 4, Phase 3 6, Phase 2/3 2, Phase 2 29, Phase 1/2 6, Phase 1 18) 2000: 87 trials (Observational 2, Not applicable 9, Phase 3 11, Phase 2/3 2, Phase 2 37, Phase 1/2 9, Phase 1 17) 2001: 81 trials (Observational 5, Not applicable 10, Phase 3 4, Phase 2/3 1, Phase 2 41, Phase 1/2 10, Phase 1 10) 2002: 96 trials (Observational 4, Not applicable 6, Phase 4 2, Phase 3 14, Phase 2/3 3, Phase 2 36, Phase 1/2 12, Phase 1 19) 2003: 86 trials (Observational 8, Not applicable 7, Phase 4 2, Phase 3 7, Phase 2 40, Phase 1/2 8, Phase 1 14) 2004: 112 trials (Observational 7, Not applicable 8, Phase 4 1, Phase 3 12, Phase 2/3 3, Phase 2 49, Phase 1/2 13, Phase 1 19) 2005: 148 trials (Observational 8, Not applicable 7, Phase 4 4, Phase 3 14, Phase 2/3 1, Phase 2 62, Phase 1/2 13, Phase 1 39) 2006: 149 trials (Other 2, Observational 15, Not applicable 6, Phase 4 1, Phase 3 8, Phase 2/3 4, Phase 2 69, Phase 1/2 19, Phase 1 25) 2007: 163 trials (Other 1, Observational 22, Not applicable 13, Phase 4 4, Phase 3 11, Phase 2/3 2, Phase 2 59, Phase 1/2 17, Phase 1 34) 2008: 166 trials (Other 2, Observational 27, Not applicable 12, Phase 4 2, Phase 3 13, Phase 2 58, Phase 1/2 19, Phase 1 33) 2009: 161 trials (Other 1, Observational 23, Not applicable 9, Phase 4 6, Phase 3 11, Phase 2/3 3, Phase 2 59, Phase 1/2 17, Phase 1 32) 2010: 151 trials (Observational 29, Not applicable 8, Phase 4 6, Phase 3 14, Phase 2/3 1, Phase 2 51, Phase 1/2 15, Phase 1 27) 2011: 155 trials (Observational 26, Not applicable 4, Phase 4 4, Phase 3 13, Phase 2/3 1, Phase 2 61, Phase 1/2 17, Phase 1 29) 2012: 139 trials (Observational 21, Not applicable 5, Phase 4 3, Phase 3 11, Phase 2/3 1, Phase 2 57, Phase 1/2 13, Phase 1 28) 2013: 166 trials (Observational 28, Not applicable 10, Phase 4 9, Phase 3 7, Phase 2/3 2, Phase 2 57, Phase 1/2 30, Phase 1 23) 2014: 160 trials (Observational 27, Not applicable 9, Phase 4 5, Phase 3 16, Phase 2/3 3, Phase 2 48, Phase 1/2 20, Phase 1 32) 2015: 148 trials (Observational 19, Not applicable 11, Phase 4 3, Phase 3 11, Phase 2/3 1, Phase 2 50, Phase 1/2 18, Phase 1 35) 2016: 160 trials (Observational 30, Not applicable 10, Phase 4 6, Phase 3 8, Phase 2/3 4, Phase 2 44, Phase 1/2 27, Phase 1 31) 2017: 152 trials (Observational 27, Not applicable 17, Phase 4 4, Phase 3 10, Phase 2/3 1, Phase 2 51, Phase 1/2 17, Phase 1 25) 2018: 157 trials (Observational 25, Not applicable 6, Phase 3 15, Phase 2/3 3, Phase 2 49, Phase 1/2 17, Phase 1 42) 2019: 159 trials (Observational 23, Not applicable 9, Phase 4 3, Phase 3 21, Phase 2/3 4, Phase 2 47, Phase 1/2 16, Phase 1 36) 2020: 162 trials (Observational 36, Not applicable 6, Phase 3 12, Phase 2/3 1, Phase 2 47, Phase 1/2 20, Phase 1 40) 2021: 199 trials (Observational 33, Not applicable 18, Phase 4 4, Phase 3 19, Phase 2/3 5, Phase 2 61, Phase 1/2 29, Phase 1 30) 2022: 175 trials (Observational 40, Not applicable 19, Phase 4 3, Phase 3 11, Phase 2/3 3, Phase 2 40, Phase 1/2 20, Phase 1 39) 2023: 164 trials (Observational 40, Not applicable 18, Phase 4 8, Phase 3 16, Phase 2/3 1, Phase 2 37, Phase 1/2 16, Phase 1 28) 2024: 191 trials (Observational 50, Not applicable 11, Phase 4 6, Phase 3 16, Phase 2/3 2, Phase 2 48, Phase 1/2 17, Phase 1 41) 2025: 159 trials (Observational 37, Not applicable 15, Phase 3 8, Phase 2 49, Phase 1/2 18, Phase 1 32)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 184
2025 159
2024 191
2023 164
2022 175
2021 199
2020 162
2019 159
2018 157
2017 152

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 200 trials starting in 2026 and about 180 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 427 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 2,790 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Bone Marrow Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 845
Phase 1/2 481
Phase 2 1,462
Phase 2/3 61
Phase 3 365
Phase 4 91
Not applicable 297
Observational 676
Expanded access 33
Unknown 1

How many Bone Marrow Diseases trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 134
Recruiting 543
Enrolling by invitation 15
Active, not recruiting 266
Available 14

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Bone Marrow Diseases trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 184
National Cancer Institute (NCI) 163
National Heart, Lung, and Blood Institute (NHLBI) 87
Bristol-Myers Squibb 56
Celgene 53

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Bone Marrow Diseases? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 333
Busulfan 203
Imatinib 151

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 390
Azacitidine MTD 224
Cytarabine IT 220
Mofetil Mycophenolate 182
Cyclosporine 0.05% 180

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Bone Marrow Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 3,484 289
Pneumonia 2,907 307
Platelet count decreased 2,007 95
Neutrophil count decreased 1,939 60
Anemia 1,851 77

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Bone Marrow Diseases? (143)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets. Rheumatology (Oxford, England) 2025 Yes
Subchondroplasty® (SCP) Provides Resolution of Symptoms and Functional Improvements in Mild-to-Moderate Knee Osteoarthritis with Persistent Bone Marrow Lesions: 12-Month Follow-Up Results from a Multicentric Open-Label Prospective Clinical Trial. Cartilage 2025 Yes
Prospective Evaluation of Clinical Outcomes of the Subchondroplasty Procedure for Treatment of Symptomatic Bone Marrow Lesions of the Knee. The journal of knee surgery 2025 Yes
Eltrombopag for Bone Marrow Failure in Fanconi Anemia: Results From the Phase II Clinical Trial FANCREV. European journal of haematology 2025 Yes
Quantitative MRI Assessment of Bone Marrow Disease in Myelofibrosis: A Prospective Study. Radiology. Imaging cancer 2025 Yes

Showing 5 of 143 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages